178 related articles for article (PubMed ID: 33749379)
21. TSPO PET imaging of natalizumab-associated progressive multifocal leukoencephalopathy.
Mahler C; Schumacher AM; Unterrainer M; Kaiser L; Höllbacher T; Lindner S; Havla J; Ertl-Wagner B; Patzig M; Seelos K; Neitzel J; Mäurer M; Krumbholz M; Metz I; Brück W; Stadelmann C; Merkler D; Gass A; Milenkovic V; Bartenstein P; Albert NL; Kümpfel T; Kerschensteiner M
Brain; 2021 Oct; 144(9):2683-2695. PubMed ID: 33757118
[TBL] [Abstract][Full Text] [Related]
22. Diffusion-weighted imaging in patients with progressive multifocal leukoencephalopathy.
Cosottini M; Tavarelli C; Del Bono L; Doria G; Giannelli M; De Cori S; Michelassi MC; Bartolozzi C; Murri L
Eur Radiol; 2008 May; 18(5):1024-30. PubMed ID: 18324406
[TBL] [Abstract][Full Text] [Related]
23. Amide proton transfer MRI differentiates between progressive multifocal leukoencephalopathy and malignant brain tumors: a pilot study.
Koike H; Morikawa M; Ishimaru H; Ideguchi R; Uetani M; Hiu T; Matsuo T; Miyoshi M
BMC Med Imaging; 2022 Dec; 22(1):227. PubMed ID: 36572873
[TBL] [Abstract][Full Text] [Related]
24. Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.
Prosperini L; de Rossi N; Scarpazza C; Moiola L; Cosottini M; Gerevini S; Capra R;
PLoS One; 2016; 11(12):e0168376. PubMed ID: 27997580
[TBL] [Abstract][Full Text] [Related]
25. Changes in Brain Volumes Are Relevant during Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: Lessons from a Case Report.
De Masi R; Orlando S; Armenise S; Spagnolo P; Capra R; Costa MC
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362428
[TBL] [Abstract][Full Text] [Related]
26. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
[TBL] [Abstract][Full Text] [Related]
27. [Neuroradiological Diagnosis of Progressive Multifocal Leukoencephalopathy (PML): Pathology of Extending/expanding Demyelinating Lesions Detected by MRI].
Shishido-Hara Y; Kanoto M
Brain Nerve; 2020 Sep; 72(9):973-986. PubMed ID: 32934187
[TBL] [Abstract][Full Text] [Related]
28. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.
Dong-Si T; Gheuens S; Gangadharan A; Wenten M; Philip J; McIninch J; Datta S; Richert N; Bozic C; Bloomgren G; Richman S; Weber T; Clifford DB
J Neurovirol; 2015 Dec; 21(6):637-44. PubMed ID: 25771865
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.
Yousry TA; Major EO; Ryschkewitsch C; Fahle G; Fischer S; Hou J; Curfman B; Miszkiel K; Mueller-Lenke N; Sanchez E; Barkhof F; Radue EW; Jäger HR; Clifford DB
N Engl J Med; 2006 Mar; 354(9):924-33. PubMed ID: 16510746
[TBL] [Abstract][Full Text] [Related]
30. Asymptomatic Progressive Multifocal Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR Imaging.
Hodel J; Outteryck O; Dubron C; Dutouquet B; Benadjaoud MA; Duhin E; Verclytte S; Zins M; Luciani A; Rahmouni A; Pruvo JP; Vermersch P; Leclerc X
Radiology; 2016 Mar; 278(3):863-72. PubMed ID: 26436861
[TBL] [Abstract][Full Text] [Related]
31. A role for susceptibility weighted imaging in progressive multifocal leukoencephalopathy.
Yap SM; Murray B; Lynch T; Kavanagh E; MacMahon P
Ir Med J; 2017 Apr; 110(4):549. PubMed ID: 28665088
[TBL] [Abstract][Full Text] [Related]
32. Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML).
Schneider R; Bellenberg B; Hoepner R; Kolb EM; Ellrichmann G; Haghikia A; Gold R; Lukas C
PLoS One; 2017; 12(4):e0176415. PubMed ID: 28445498
[TBL] [Abstract][Full Text] [Related]
33. Pathology for severe inflammatory PML with PD1/PD-L1 expression of favorable prognosis: What's a prognostic factor for PML-IRIS?
Shishido-Hara Y; Akimoto J; Fukami S; Kohno M; Matsubayashi J; Nagao T
Neuropathology; 2024 Feb; 44(1):47-58. PubMed ID: 37424276
[TBL] [Abstract][Full Text] [Related]
34. High b-value diffusion-weighted imaging in progressive multifocal leukoencephalopathy in HIV patients.
Godi C; De Vita E; Tombetti E; Davagnanam I; Haddow L; Jäger HR
Eur Radiol; 2017 Sep; 27(9):3593-3599. PubMed ID: 28168372
[TBL] [Abstract][Full Text] [Related]
35. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
[TBL] [Abstract][Full Text] [Related]
36. Review of progressive multifocal leukoencephalopathy and natalizumab.
Aksamit AJ
Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
[TBL] [Abstract][Full Text] [Related]
37. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.
Boster A; Hreha S; Berger JR; Bao F; Penmesta R; Tselis A; Endress C; Zak I; Perumal J; Caon C; Vazquez J; Tyler KL; Racke MK; Millis S; Khan O
Arch Neurol; 2009 May; 66(5):593-9. PubMed ID: 19433659
[TBL] [Abstract][Full Text] [Related]
38. Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate.
Scarpazza C; Signori A; Cosottini M; Sormani MP; Gerevini S; Capra R
Mult Scler; 2020 Sep; 26(10):1227-1236. PubMed ID: 31144589
[TBL] [Abstract][Full Text] [Related]
39. A Punctate Magnetic Resonance Imaging Pattern in a Patient with Systemic Lupus Erythematosus Is an Early Sign of Progressive Multifocal Leukoencephalopathy: A Clinicopathological Study.
Ishii J; Shishido-Hara Y; Kawamoto M; Fujiwara S; Imai Y; Nakamichi K; Kohara N
Intern Med; 2018 Sep; 57(18):2727-2734. PubMed ID: 29709947
[TBL] [Abstract][Full Text] [Related]
40. MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.
Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; de Vos M; Richert ND; Uitdehaag BM; Barkhof F; Killestein J;
J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):879-84. PubMed ID: 26369555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
